The Use of ADV6209 for Premedication in Pediatric Anesthesia
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral
Author: Tamas Sohajda
Cyclolab R&D Director
Axsome Therapeutics Announces Acceleration of MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today
Enrollment completed of Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated announced completion of enrollment of the Company’s Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of
Phase I clinical trial posted on Relative Bioavailability of CE-Iohexol (Captisol-enabled™ Iohexol) Injection
This study is designed to compare the bioavailability of the test Product (CE-Iohexol Injection) and the reference product Iohexol Injection
CTD Holdings Announces Plan to Launch Clinical Trial of Trappsol (R) Cyclo (TM) in Alzheimer’s Disease
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
Sage Therapeutics Announces FDA Approval of ZULRESSO™ (SBECD-enabled brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression
Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms
CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
CTD Announces Partnership with United BioSource
CTD Holdings, a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need,
The monograph of SBECD is official in the European Pharmacopeia
As of January 1st, 2019, besides the long valid (August 1st, 2012) monograph in USP NF for Betadex Sulfobutyl Ether